2016
DOI: 10.1007/s10147-016-1001-1
|View full text |Cite
|
Sign up to set email alerts
|

Donor interleukin 6 gene polymorphisms predict the recurrence of hepatocellular carcinoma after liver transplantation

Abstract: Our data suggest that donor IL6 rs2069852 polymorphisms may be a potential genetic marker for HCC recurrence after liver transplantation in the Han Chinese population.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
3
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 44 publications
1
3
0
Order By: Relevance
“…In addition, the TNM stage, microvascular invasion and the donor Rap1A rs494453 genotype AG/GG were independent risk factors for OS. These results were consistent with those of previous studies [7,22,23].…”
Section: Discussionsupporting
confidence: 94%
“…In addition, the TNM stage, microvascular invasion and the donor Rap1A rs494453 genotype AG/GG were independent risk factors for OS. These results were consistent with those of previous studies [7,22,23].…”
Section: Discussionsupporting
confidence: 94%
“…Given its pivotal role in the proliferation, survival, and activation of CD8 + T cells and NK cells, IL-15 has been identified as an antitumor cytokine in several cancers, including neuroblastoma, HCC, and breast and colorectal cancer [ 27 31 ]. A close relationship between cytokine gene polymorphisms and HCC and HCC prognosis has been reported in recent years [ 10 , 20 , 21 ]. The potential association between the IL-15 gene polymorphisms and HCC recurrence and prognosis has been described in several studies.…”
Section: Discussionmentioning
confidence: 93%
“…Although several criteria are available for transplant patient selection, they have limitations for determining clinical outcome. Molecular markers and genetic variants could provide supplemental and useful information for predicting the clinical outcome and improve the selection of patients for adjuvant therapies after LT in addition to the clinical factors [ 9 , 10 ]. As such, it is a challenge to identify patients who are with a greater risk for HCC recurrence after LT and potential biomarkers for prognosis prediction.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation